Again, please refer to the Quarterly Activities Report & Appendix 4C dated 29-07-2021
Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD
The manufacture of a batch of ATL1102 active pharmaceutical ingredient (API) for the Phase IIb trial was undertaken in North America by Nitto Denko Avecia (Avecia).Upon completion of the manufacture of this batch of API, the material was then shipped to Contract, Parenteral (injectable) Drug Product Manufacturer Pyramid Laboratories (Pyramid) in Costa Messa, Southern California and formulated into injectable product for use in the Phase IIb trial. Importantly, both Avecia and Pyramid have commercial capabilities to support advanced clinical trials and subsequent commercial supply.
So, I would assume the manufacture of the batch API hasn't finished yet...
- Forums
- ASX - By Stock
- PER
- Ann: Antisense Therapeutics transitions to new Board Chair
Ann: Antisense Therapeutics transitions to new Board Chair, page-102
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
-0.002(2.30%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.7¢ | 8.7¢ | 8.3¢ | $82.04K | 969.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 200841 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 102187 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 200841 | 0.083 |
2 | 143500 | 0.081 |
2 | 106250 | 0.080 |
3 | 132078 | 0.079 |
2 | 120924 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 102187 | 2 |
0.087 | 429525 | 2 |
0.088 | 457142 | 2 |
0.089 | 295000 | 3 |
0.090 | 494374 | 5 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |